Drug Profile
Omilancor - Landos Biopharma
Alternative Names: BT 11Latest Information Update: 25 Oct 2023
Price :
$50
*
At a glance
- Originator Landos Biopharma
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Inflammation mediator inhibitors; LANCL2 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease; Ulcerative colitis
- Preclinical Atopic dermatitis; Eosinophilic oesophagitis; Psoriasis
Most Recent Events
- 23 Oct 2023 Efficacy and adverse events data from phase II trial in Crohn's Disease released by NImmune Biopharma
- 23 Oct 2023 Pharmacodynamics data from preclinical trial in Ulcerative Colitis released by NImmune Biopharma
- 23 Oct 2023 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from phase II trial in Ulcerative colitis released by NImmune Biopharma